Abstract: Radiation necrosis (RN) is one of the complications of radiotherapy. Angiogenesis is a key factor underlying the development of RN, and Endostar, a safe and well-tolerated recombinant human endostatin, has been used to treat a variety of tumors. Thus far, however, no definitive reports on the use of Endostar for RN treatment have been reported. Here, we report the successful treatment of one patient with symptomatic brain radiation necrosis (BRN) using Endostar in combination with short-term hyperbaric oxygen therapy (HBO). One triple-negative breast cancer patient with recurrent brain metastatic lesions after standard chemoradiotherapy was referred to a specialty center outside our hospital for stereotaxic radiotherapy. Two months later, the patient showed deteriorating clinical symptoms, and magnetic resonance imaging (MRI) showed radiation necrosis with significant surrounding edema. The patient had a poor response to mannitol and steroids. After diagnosing this patient with BRN, we began short-term HBO therapy and intravenously administered Endostar for 4 cycles. The patient responded well to this strategy, showing rapidly and dramatically improved MRI findings and clinical symptoms. No tumor progression was observed at 10 months after treatment. Endostar in combination with short-term HBO therapy had marked effects on symptomatic BRN. However, additional large-scale, double-blinded, controlled trials are necessary to confirm the clinical effect of Endostar in combination with a short-term HBO therapy regimen on BRN.
Introduction
Research indicates that triple-negative breast cancer (TNBC) has a propensity for visceral metastasis to the brain and lung. 1, 2 The incidence of brain metastasis has been steadily increasing in recent years. 3 Therapeutic irradiation is an important modality for locally controlling disease associated with metastatic brain tumors. [4] [5] [6] [7] Recently, high-dose radiotherapies, such as intensity-modulated radiation therapy, proton beam radiotherapy, and boron neutron capture therapy, have been used for the treatment of brain tumors and have led to better expected outcomes than those achieved with conventional radiotherapy. Although the central nervous system (CNS) was first thought to be highly radioresistant, studies have shown that the CNS, particularly the white matter in the deep part of the brain, is more radioresponsive than previously believed. [8] [9] [10] Local radiation injuries can occur from as early as a few months to 10 or more years after radiotherapy. 11 Brain radiation necrosis (BRN) is an adverse event widely known to be associated with therapeutic irradiation to the CNS and focal injuries resulting from late radiation effects, causing focal neurological abnormalities. Diagnosis and treatment of BRN remain challenging because it is not easily distinguishable from tumor recurrence without pathological examination of a resected sample, 12 and the therapeutic strategies for tumor progression and treatment-related RN are completely different. RN initially responds to corticosteroids, but progressive RN is refractory to medical treatment. Vascular endothelial growth factor (VEGF) has been reported to play an important role in the development of RN, and blocking the function of VEGF has been reported to be effective at treating RN and reducing perilesional edema. [13] [14] [15] Endostar is a modified and recombinant human endostatin that was first used for the treatment of nonsmall-cell lung cancer (NSCLC), and similar to endostatin, Endostar blocks the VEGF signaling pathway. The use of Endostar to treat radiation encephalopathy has not been indicated in the literature. Herein, we report the successful treatment of one patient with BRN after radiotherapy using Endostar in combination with a single course of hyperbaric oxygen (HBO) therapy.
Case report
A 45-year-old female patient was diagnosed with clinical stage breast cancer (IIIC, pT2N3M0) in her right breast. Pathological results revealed that the tumor was invasive ductal carcinoma, ER(-), PgR(-), and HER2(-). After treatment via a modified radical right mastectomy, the patient received six cycles of adjuvant chemotherapy with a docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (TAC) regimen; capecitabine as a single-drug treatment for three cycles; and adjuvant radiation (DT 50 Gy). Ten months after surgery, the patient complained of headache and dizziness. Magnetic resonance imaging (MRI) revealed an enhanced solitary mass (19×22×25 mm) with a surrounding area of low intensity in the right basal ganglia, associated with left frontal lobe metastases ( Figure 1A) , and the patient was consequentially diagnosed with brain metastasis. Contrast-enhancement T1-weighted images showed that the enhanced mass was surrounded by a hypointense area, a finding consistent with edema; no other metastases were observed. The patient received whole-brain radiotherapy (3,860 cGy) and increased doses of radiotherapy to the metastatic carcinoma sites (2,000 cGy). After radiotherapy, the patient was treated with temozolomide for two cycles.
Two months after brain radiotherapy, a follow-up MRI revealed that the cerebral metastatic tumor volumes in the right basal ganglia and left frontal lobe were significantly reduced, and the therapeutic effect was evaluated as a complete response (CR) ( Figure 1B ). Seven courses of autologous dendritic cell/cytokine-induced killer cell (DC-CIK) therapy were administered, and temozolomide therapy was continued for four cycles. The patient showed stable disease for nineteen months.
However, thirty-three months after the first brain radiotherapy, the patient once again complained of headache and dizziness, and a cranial MRI reexamination revealed metastatic brain tumor recurrence and progression ( Figure 2A ). Once again, the patient was administered four cycles of temozolomide. Two months later, an MRI scan revealed slow progression of the brain tumor metastases ( Figure 2B) , and the patient then underwent stereotaxic radiotherapy for brain tumor metastases at the Nanfang Hospital of Nanfang Medical University (dosage not stated). A few days later, the patient developed headache, dizziness and muscle strength degeneration; these symptoms were progressively exacerbated. The MRI results showed brain metastases and radiation encephalopathy. An enhanced solitary mass (53×28×20 mm) with a surrounding area of low intensity was observed in the bilateral frontal lobe and genu of the corpus callosum ( Figure 3A) . We treated the patient with mannitol and steroids to reduce the intracranial pressure and further limit the damage caused by cerebral edema. The patient's condition was wavering and lingered, and her quality of life deteriorated. Next, the patient was treated with tamoxifen to prevent tumor recurrence and progression. Three months later, an MRI reexamination showed radiation encephalopathy that could not exclude brain metastases; the lesion area was not decreased after treatment ( Figure 3B ).
Considering that radiation encephalopathy could have occurred, we attempted to adapt HBO therapy. After only one treatment, the patient felt much better; her headache and dizziness disappeared, and her muscle strength was obviously restored. We continued to administer HBO therapy once a day for ten days, and the patient subsequently received four cycles of the Endostar regimen (30 mg of a continuous infusion, D1~7). Two and six months after Endostar treatment, MRI analysis showed that the areas of BRN and edema had decreased significantly ( Figure 4A and B).
Discussion
The incidence of CNS metastases among patients with advanced TNBC is as high as 46%, 16 reducing the brain metastatic tumor volume and maintaining a nonrecurrent status. High incidence rates of RN and symptomatic changes have been associated with high-dose radiotherapies. 18, 19 Therefore, developing high-dose radiotherapies and successfully treating BRN are also important.
Several studies have reported that HBO therapy could both decrease intracranial pressure and reduce the incidence and severity of BRN symptoms, including headaches, new seizure onset, general cognitive decline, and focal neurological deficits. [20] [21] [22] However, most of these studies were small and retrospective, and most patients received steroids concurrently; thus, determining whether the symptoms of RN are improved with longer durations of steroid treatment or HBO is difficult. 23 Furthermore, the dose of radiation administered by the outside specialty center was not clear, and metastatic lesion progression or deterioration could not be ruled out when relying solely on the MRI results. Decisions regarding therapy for BRN are often affected by whether the patient has received a definitive diagnosis. Therefore, rather than adopting HBO therapy, we initially treated this patient with mannitol and steroids to reduce the intracranial pressure and to limit further damage caused by cerebral edema. However, the curative effect of this strategy was extremely poor. Considering that BRN could have occurred, we attempted to adapt HBO therapy, and interestingly, the clinical symptoms of intracranial hypertension were significantly reduced. This finding suggests that when radiation encephalopathy is highly suspected, disease progression should not be ruled out, and applying short-term HBO therapy might be a good treatment choice. The pathophysiological mechanisms underlying BRN are thought to mainly consist of endothelial abnormalities and elevated levels of cytokines, eg VEGF, resulting in increased vascular permeability, extracellular edema and, ultimately, hypoxia and necrosis. 24 Research indicates that VEGF knockout mice are resistant to radiation injury, 25 and VEGF-producing astrocytes could concentrate in perinecrotic areas and be a universal cause of pathological angiogenesis in RN and subsequent perilesional edema. 13, 26 These results indicate that VEGF is responsible for factors related to deep RN growth. As a selective inhibitor of VEGF biological effects, the monoclonal antibody bevacizumab offers symptomatic relief, a reduction in steroid requirements, and a dramatic radiographic response and appears to be a promising agent for the treatment of BRN. 15, [27] [28] [29] However, most patients experience recurrence after bevacizumab is discontinued, and some patients even become resistant to the drug and experience retreatment failure, followed by cancer progression. 30, 31 Endostar, a new recombinant human endostatin expressed and purified in Escherichia coli, was approved by China's State Food and Drug Administration (SFDA) for the treatment of NSCLC in 2005. The anti-angiogenic activity of endostatin is not the result of a single molecular action but is very complex. Endostatin activity reportedly leads to the induction of endothelial cell apoptosis, cell cycle arrest and suppression of endothelial cell proliferation and migration via a complex signaling system, 32-36 thereby powerfully suppressing neovascularization. Research has indicated that endostatin alone or in combination with radiotherapy and chemotherapy could inhibit the progression of multiple cerebral metastases in various types of tumors. [37] [38] [39] [40] [41] To the best of our knowledge, this is the first report to evaluate the role of Endostar for the treatment of BRN resulting from any tumor type. In this case, Endostar effectively improved the symptoms of intracranial hypertension, significantly reduced the area of BRN and maintained the nonrecurrent status in the brain. It is also worth noting that the patient resumed a normal life and worked after treatment, and no recurrence was observed during a follow-up period of 10 months. This case report provides a useful reference for the clinical management of patients with BRN. However, additional research is required to verify the effectiveness of Endostar in combination with a short-term HBO therapy regimen on BRN.
Conclusion
Endostar in combination with short-term HBO therapy had marked effects on symptomatic BRN, significantly reducing the area of BRN and maintaining the nonrecurrent status. Additional large-scale, double-blinded, controlled trials are necessary to confirm the clinical effect of this therapeutic regimen on BRN.
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